Health State Utilities for Acute Myeloid Leukaemia: A Time Trade-off Study
Acute myeloid leukaemia (AML) is an aggressive haematological cancer associated with significant humanistic impact. The current study assessed how the general public in the United Kingdom (UK) values AML health states.
The composite time trade-off (cTTO) methodology was employed to elicit health state utilities in AML. Pertinent AML literature related to symptom and quality-of-life impact including physical, functional and emotional well-being, as well as the safety profile of AML treatments, were taken into consideration for drafting health state descriptions. Ten health states included in the study were newly diagnosed AML, induction, consolidation, maintenance, long-term follow-up, relapsed/refractory, stem-cell transplant (SCT) procedure, SCT recovery, SCT long-term follow-up with complications and SCT long-term follow-up without complications. The descriptions were validated by haematologists and nurse specialists for clinical accuracy and completeness. A total of 210 individuals from the general UK population participated in the cTTO interviews. Descriptive statistics were computed for health state utility values.
The mean age of the participants was 44.0 years (standard deviation [SD] 14.9, range 18–81) and comprised 129 (61.4%) female participants. The utility values ranged from 0.94 (SD 0.13) for SCT long-term follow-up without complications to − 0.21 (SD 0.62) for the SCT procedure.
The study provides health utilities for a range of AML health states, with the SCT procedure health state being valued worse than death. The utilities obtained in this study can be employed as inputs in cost-effectiveness analyses of AML therapies.
We thank Krystallia Pantiri, Lisette Nientker, and Nick Durno for conducting the interviews. We also thank Amrita Ostawal and Jarjieh Fang for reviewing the manuscript, and Jarjieh Fang for providing editorial support.
Compliance with Ethical Standards
Namita Joshi, Marja Hensen and Kathy Lasch are employees of Pharmerit International, which received funding by Novartis Global to conduct the study. Weiwei Xu was an employee of Pharmerit International at the time of the study, which received funding by Novartis Global to conduct the study. Sachin Patel is employed by Novartis UK. Elly Stolk is employed by The EuroQol Research Foundation and served as the methodology advisor on this study.
Conflict of interest
Namita Joshi, Marja Hensen, Weiwei Xu and Kathy Lasch are employees of Pharmerit International, a consultancy which received funding from Novartis Global to conduct the study. Sachin Patel is an employee of Novartis UK. Elly Stolk received a consulting fee from Pharmerit International for serving as a methodology advisor on this study.
- 2.Union for International Cancer Control. Acute myelogenous leukemia and acute promyelocytic leukemia. 2014. http://www.who.int/selection_medicines/committees/expert/20/applications/AML_APL.pdf. Accessed 14 Aug 2018.
- 3.Cancer Research UK. 2015. https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/leukaemia-aml/incidence. Accessed 14 Aug 2018.
- 10.Deschler B, Ihorst G, Platzbecker U, Germing U, Marz E, de Figuerido M, et al. Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome. Haematologica. 2013;98:208–16.CrossRefGoogle Scholar
- 17.Grulke N, Albani C, Bailer H. Quality of life in patients before and after haematopoietic stem cell transplantation measured with the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Core Questionnaire QLQ-C30. Bone Marrow Transplant. 2012;47:473–82.CrossRefGoogle Scholar
- 18.Brazier JE, Rowen D. NICE DSU technical support document 11: alternatives to EQ-5D for generating health state utility values. London: National Institute for Health and Care Excellence (NICE); 2011.Google Scholar
- 23.Stolk E, Ludwig K, Rand Hendrikson K, Van Hout B, Ranos Goñi J. Overview, update and lessons learned from the international EQ-5D-5L valuation work: version 2 of the EQ-5D-5L valuation protocol (Submitted).Google Scholar
- 26.National Institute for Health and Care Excellence. NICE pathway: myeloid leukaemia. 2017. https://pathways.nice.org.uk/pathways/blood-and-bone-marrow-cancers/myeloid-leukaemia. Accessed 1 Jan 2018.
- 29.Office for National Statistics. Overview of the UK population: February 2016. 2016. https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/articles/overviewoftheukpopulation/february2016. Accessed 10 Jul 2018.